Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa multiple-dose escalation study of ABP2111Na in overweight or obese adults
ChiCTR2400089810Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ABP2111Na in obesity and Overweight (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Safety and tolerability. Started Sep 2024; status: recruiting.
02
Drugs
ABP2111Na
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on ChiCTR2400089810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089810.